UPFRONT OVERALL SURVIVAL MODELLING IN COMPARISON TO REAL WORLD DATA: LENALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS IN SOUTH KOREA

被引：0
|
作者：
Felix, J. [1 ]
Vandewalle, B. [1 ]
Almeida, J. [1 ]
Valeska, A. [1 ]
机构：
[1] Exigo Consultores, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.073
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM20
引用
收藏
页码：A729 / A729
页数：1
相关论文
共 50 条
  • [41] Lenalidomide maintenance in R2-ISS stratified multiple myeloma patients - real world evidence
    Radocha, Jakub
    Jungova, Alexandra
    Pour, Ludek
    Spicka, Ivan
    Minarik, Jiri
    Jelinek, Tomas
    Jindra, Pavel
    Stork, Martin
    Pika, Tomas
    Sedlak, Frantisek
    Popkova, Tereza
    Novakova, Denisa
    Sykora, Michal
    Pavlicek, Petr
    Heindorfer, Adriana
    Wrobel, Marek
    Gregora, Evzen
    Mikula, Peter
    Obernauerova, Jarmila
    Ullrychova, Jana
    Stejskal, Lukas
    Kessler, Petr
    Maisnar, Vladimir
    Hajek, Roman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S122 - S123
  • [42] Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation
    Xu, Tianhong
    Yang, Yang
    Li, Jing
    Xu, Jiadai
    Wang, Wenjing
    Wang, Yawen
    Maihemaiti, Aziguli
    Ren, Liang
    Lan, Tianwei
    Zhou, Chi
    Li, Panpan
    Wang, Pu
    Liu, Peng
    ANNALS OF HEMATOLOGY, 2023, 102 (05) : 1171 - 1184
  • [43] Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation
    Tianhong Xu
    Yang Yang
    Jing Li
    Jiadai Xu
    Wenjing Wang
    Yawen Wang
    Aziguli Maihemaiti
    Liang Ren
    Tianwei Lan
    Chi Zhou
    Panpan Li
    Pu Wang
    Peng Liu
    Annals of Hematology, 2023, 102 : 1171 - 1184
  • [44] Real world treatment pattern trends in patients with multiple myeloma in the US
    Song, Xue
    Cong, Ze
    Wilson, Kathleen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 118 - 118
  • [45] Patient characteristics and burden in lenalidomide refractory multiple myeloma patients in Europe: a real-world survey
    Gay, Francesca
    Mendes, Joao
    Luke, Emily
    Kluth, Caspian
    Salmon, Phoebe
    Bailey, Abigail
    Ribbands, Amanda
    Martinez-Lopez, Joaquin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S294 - S295
  • [46] ANALYSIS OF OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS WITH 33 LINES OF THERAPY INCLUDING A PI AND AN IMID, OR DOUBLE REFRACTORY TO A PI AND AN IMID USING REAL WORLD DATA
    Usmani, S.
    Desai, A.
    Ahmadi, T.
    Ng, Y.
    Sung, G.
    Mehra, M.
    HAEMATOLOGICA, 2015, 100 : 504 - 505
  • [47] Real-World Treatment Patterns, Outcomes, Health Care Resource Utilization and Cost Burden of Multiple Myeloma in South Korea Using the National Claims Data
    Park, YoungJu
    Park, Sung Soo
    Yoon, Soomin
    Jeong, Jihyeon
    Lee, Doik
    Kim, Kihyun
    BLOOD, 2023, 142
  • [48] REAL WORLD DATA OF DARATUMUMAB TREATMENT IN PATIENT WITH MULTIPLE MYELOMA: A PORTUGUESE STUDY
    Gomes, A.
    Araujo, A.
    Pio, J.
    Pontes, C.
    Bergantim, R.
    Medeiros, J.
    Martins, O.
    Duarte, A.
    VALUE IN HEALTH, 2023, 26 (12) : S45 - S45
  • [49] Ixazomib/Lenalidomide/Dexamethasone (IRd) in relapsed refractory Multiple Myeloma (RRMM) - retrospective real-world data from Germany and comparison to literature
    Roesner, A.
    Wenger, S.
    Brioli, A.
    von Lilienfeld-Toal, M.
    Klaiber-Hakimi, M.
    Fehr, E. M.
    Munder, M.
    Epp, K.
    Trautmann-Grill, K.
    Engelhardt, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 235 - 236
  • [50] Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary
    Lovas, Szilvia
    Al-Ali, Nora Obajed
    Varga, Gergely
    Szita, Virag
    Alizadeh, Hussain
    Plander, Mark
    Rajnics, Peter
    Illes, Arpad
    Szemlaky, Zsuzsa
    Mikala, Gabor
    Varoczy, Laszlo
    PATHOLOGY & ONCOLOGY RESEARCH, 2022, 28
12345